Although authorities have not yet established any cause or link, families in the Orange County community of Ladera Ranch ...

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertibSAN DIEGO, July 17, 2026 (GLOBE ...

TikToker Nara Smith shared encouraging news: her and Lucky Blue Smith’s 2-year-old daughter Whimsy is in remission after ...

Researchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and ...

Researchers have made important strides in understanding and treating diffuse midline gliomas, which were long seen as a ...

A neuro-oncologist who treats patients with the most aggressive brain cancer shares the warning signs she looks for in her ...

We’re making essentially your immune system do a better job at recognition of the tumor and elimination of the tumor,” one ...

Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company ...

The therapy was first granted accelerated approval for solid tumors in 2022 based on the ongoing LIBRETTO-001 trial in adults and another pediatric trial.

A preclinical study finds that combining atovaquone with platelet-derived growth factor receptor inhibitors reduced ovarian cancer tumoroid viability.

Traditional approval establishes confirmed clinical benefit for selpercatinib in tumor-agnostic RET fusion–positive solid tumors after progression or when no satisfactory options exist. LIBRETTO-001 ...

We’ve built global highways for approved medicines and left clinical trial access on something closer to dirt roads.